Fig. 3.

Exscien1-III prevents adverse cardiac remodeling and preserves cardiac function after transverse aortic constriction (TAC). A: experimental protocol for the TAC cardiac failure study. Mice were subjected to TAC surgery, and Exscien1-III or vehicle (Veh) treatment was administered daily via intraperitoneal injection starting 3 wk post-TAC and continued until the 12-wk end point. Echocardiography was performed at baseline and every 2 wk post-TAC to assess left ventricular (LV) end-diastolic dimension (LVEDD; B), LV end-systolic dimension (LVESD; C), LV posterior wall thichness at diastole (LVPWd; D), and LV ejection fraction (LVEF; E). *P < 0.05 vs. Veh; **P < 0.01 vs. Veh.